Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q1

2160.TEDINET S100QRIK
Period2023-01-01 → 2023-03-31
Filed2023-05-15
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥4.2bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Revenue¥17.4bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥3.9bn2022-01-01 → 2022-03-31Cons.Revenue IFRS
Operating income¥398m2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Operating income¥479m2022-01-01 → 2022-03-31Cons.Operating profit loss IFRS
Profit before tax−¥65m2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Profit before tax¥768m2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥347m2022-01-01 → 2022-03-31Cons.Profit loss before tax IFRS
Net income (owners)−¥3m2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥389m2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥351m2022-01-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income−¥342m2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Net income−¥868m2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥72m2022-01-01 → 2022-03-31Cons.Profit loss IFRS
Total assets¥34.1bnat 2023-03-31Cons.Assets IFRS
Total assets¥33.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥32.6bnat 2022-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥14.3bnat 2023-03-31Cons.Liabilities IFRS
Total liabilities¥14.1bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥19.8bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥19.8bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥20.5bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥19.3bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥21.2bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥21.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥20.3bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥10.6bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.0bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.8bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.4bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥710m2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥393m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥426m2022-01-01 → 2022-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥1.2bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥4.1bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥298m2022-01-01 → 2022-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥52m2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥646m2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥331m2022-01-01 → 2022-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-0.062023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥8.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥7.42022-01-01 → 2022-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-0.062023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.112022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥7.362022-01-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio62.2%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.8%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.4%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥23m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥23m
jpcrp040300-q1r_E05712-000Medical Devicereportable segmentrevenue2023-01-01 → 2023-03-31¥623m
jpcrp040300-q1r_E05712-000Medical Devicereportable segmentrevenue external2023-01-01 → 2023-03-31¥600m
jpcrp040300-q1r_E05712-000Medical Devicereportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥23m
jpcrp040300-q1r_E05712-000Medical Devicereportable segmentsegment profit2023-01-01 → 2023-03-31¥248m
jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segmentrevenue2023-01-01 → 2023-03-31¥3.6bn
jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segmentrevenue external2023-01-01 → 2023-03-31¥3.6bn
jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segmentsegment profit2023-01-01 → 2023-03-31¥149m
—segment totalrevenue2023-01-01 → 2023-03-31¥4.2bn
—segment totalrevenue external2023-01-01 → 2023-03-31¥4.2bn
—segment totalrevenue intersegment2023-01-01 → 2023-03-31¥23m
—segment totalsegment profit2023-01-01 → 2023-03-31¥398m
jpcrp040300-q1r_E05712-000Medical Devicereportable segmentrevenue2022-01-01 → 2022-03-31¥532m
jpcrp040300-q1r_E05712-000Medical Devicereportable segmentrevenue external2022-01-01 → 2022-03-31¥532m
jpcrp040300-q1r_E05712-000Medical Devicereportable segmentsegment profit2022-01-01 → 2022-03-31¥255m
jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segmentrevenue2022-01-01 → 2022-03-31¥3.4bn
jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segmentrevenue external2022-01-01 → 2022-03-31¥3.4bn
jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segmentsegment profit2022-01-01 → 2022-03-31¥224m
—segment totalrevenue2022-01-01 → 2022-03-31¥3.9bn
—segment totalrevenue external2022-01-01 → 2022-03-31¥3.9bn
—segment totalsegment profit2022-01-01 → 2022-03-31¥479m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 547
ItemContextValueUnit
Other fin cf IFRSPrior1YTDDuration-5855000JPY
Other fin cf IFRSCurrentYTDDuration－JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-331129000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration-51798000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration639300000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration129156000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration435597000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration-452460000JPY
Cash and cash equivalents IFRSPrior2YearInstant14352133000JPY
Cash and cash equivalents IFRSPrior1YearInstant11049310000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant14787730000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant10596849000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E05712-000PharmaceuticalReportableSegmentMember3401937000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E05712-000MedicalDeviceReportableSegmentMember531552000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember3933490000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration3933490000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05712-000PharmaceuticalReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05712-000MedicalDeviceReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05712-000PharmaceuticalReportableSegmentMember3401937000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05712-000MedicalDeviceReportableSegmentMember531552000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember3933490000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue IFRSPrior1YTDDuration3933490000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E05712-000PharmaceuticalReportableSegmentMember223638000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E05712-000MedicalDeviceReportableSegmentMember255288000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember478926000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Operating profit loss IFRSPrior1YTDDuration478926000JPY
Finance income IFRSPrior1YTDDuration54672000JPY
Finance costs IFRSPrior1YTDDuration186173000JPY
Profit loss before tax IFRSPrior1YTDDuration347425000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q1r_E05712-000PharmaceuticalReportableSegmentMember3606336000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q1r_E05712-000MedicalDeviceReportableSegmentMember599799000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember4206135000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentYTDDuration4206135000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E05712-000PharmaceuticalReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E05712-000MedicalDeviceReportableSegmentMember22896000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember22896000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-22896000JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E05712-000PharmaceuticalReportableSegmentMember3606336000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E05712-000MedicalDeviceReportableSegmentMember622695000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember4229032000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-22896000JPY
Revenue IFRSCurrentYTDDuration4206135000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-03-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass